Study of the Safety and Effectiveness of JUVÉDERM VOLUX™ XC Injectable Gel for Restoring Jawline Definition

PHASE3CompletedINTERVENTIONAL
Enrollment

206

Participants

Timeline

Start Date

November 12, 2018

Primary Completion Date

February 4, 2020

Study Completion Date

January 26, 2021

Conditions
Jawline Definition
Interventions
DEVICE

VOLUX XC

Participants will be treated with VOLUX XC hyaluronic acid (HA) injectable gel on day 1 with optional touch-up at day 30 and optional maintenance treatment at Month 12.

OTHER

No-treatment control

No-treatment during the control period. Optional delayed-treatment with VOLUX XC (initial with optional touch-up) at the beginning of the Post-Control period.

Trial Locations (19)

10003

Center aesthetic and dermatology, New York

10016

Laser & Skin Surgery Center of New York, New York

10549

The Center for Dermatology, Cosmetic & Laser Surgery, Mount Kisco

12110

Williams Center, Latham

20037

Center for Dermatology and Dermatologic Surgery, Washington D.C.

20769

Callender Center for Clinical Research, Glenn Dale

21030

MDLSV, Hunt Valley

22209

SkinDC, Arlington

27517

Aesthetic Solutions, PA., Chapel Hill

33134

Hevia Cosmetic Dermatology, Coral Gables

33137

Baumann Cosmetic and Research Institute, Miami

33146

Skin Research Institute LLC, Coral Gables

34209

Susan H Weinkle, MD, Bradenton

35205

Total Skin and Beauty Dermatology Center, PC, Birmingham

60611

DeNova Research dba Arano, LLC, Chicago

77056

Suzanne Bruce and Associates, P.A., The Center for Skin Research, Houston

77401

Bellaire Dermatology Associates, Bellaire

90025

Westside Aesthetics, Los Angeles

95401

Artemedica, Santa Rosa

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Allergan

INDUSTRY